- Rupee Rundown
- Posts
- Big RBI Decision Coming: What to Expect on Dec 6?
Big RBI Decision Coming: What to Expect on Dec 6?
Hello,
Markets rose by 1% yesterday, with IT stocks leading the gains. The Nifty IT index surged nearly 2%, reaching an all-time high and crossing the 45,000 mark for the first time intraday. Today's market sentiment will likely be influenced by the Reserve Bank of India (RBI) Governor Shaktikanta Das, who is set to announce the fifth monetary policy for the 2024-25 financial year today (Friday, December 6), following a three-day meeting that began on December 4, 2024.
As of 05/12/24
Sensex and Nifty extended their gains on Thursday, climbing 1% as IT stocks surged amid a US market rally and renewed foreign fund inflows.
Indian IT stocks rose for the fifth consecutive session on December 5, driven by Federal Reserve Chair Jerome Powell's comments at the New York Times DealBook Summit, highlighting the resilience of the US economy, which accounts for 60-70% of IT companies' revenue.
Nifty 50 | 0.98% | 24,708.40 |
BSE Sensex | 1.00% | 81,765.86 |
Nifty Bank | 0.63% | 53,603.55 |
Nifty IT | 1.95% | 44,806.40 |
Nifty Vix | 0.54% | 14.53 |
10 yr Bond | 1.54% | 6.789 |
USD>INR | 0.00% | 84.710 |
Source: Moneycontrol
CDSL +8.05%
Shares of CDSL surged 8% to a record high of ₹1,865 on December 5, marking their biggest gain in eight weeks amid heavy volumes.
Over two crore shares were traded on the BSE and NSE, significantly surpassing the one-month average of 42 lakh shares. Year-to-date, the stock has more than doubled, rising over 100%, compared to the Nifty 50's 12% gain.
Divi’s Laboratories (2.51%)
Shares fell 3% after Novartis failed to convince a US appeals court to block MSN Pharmaceuticals' generic version of its heart drug Entresto.
The US Court of Appeals for the Federal Circuit upheld an earlier ruling by a Delaware judge in August, stating Novartis was unlikely to succeed in its patent lawsuit against MSN. This paves the way for MSN to launch the first US generic for Entresto. Divi's Labs holds a CDMO contract with Novartis for the drug.
All eyes are on the RBI as liquidity concerns rise amid reduced FPI flows. (ET)
Nomura says the rupee's weakness won't stop India's central bank from cutting rates. (RT)
Electric vehicle sales soar under the PM E-DRIVE scheme. (ET)
Piyush Goyal says the government is open to exploring alternative financing models for MSMEs. (Mint)
Suraksha Diagnostic IPO allottees are likely to witness modest listing gains today. (MC)
This week’s mainboard IPO schedule
Suraksha Diagnostic
Offering Period: 29 November - 03 December, 2024
Listing Date: 06 December, 2024
Issue Price: 420-441
Lot Size: 34
Property Share REIT
Offering Period: 02 December - 04 December, 2024
Listing Date: 09 December, 2024
Issue Price: 10,00,000-10,50,000
Lot Size: 1
M&A / Investments
Debt
VC
Category | Company | Amount |
---|---|---|
Cleantech | Rs 50 crore ($5.9Mn) | |
Fintech | Rs 21 crore ($2.5Mn) | |
Clothing | Rs 8 crore ($945k) | |
Healthcare | Rs 5.9 crore ($700k) | |
Premium Retail | Rs 5 crore ($590k) | |
Social Media | Rs 4.2 crore ($500k) |
Add us on LinkedIn!
What did you think of today's email?You can add more feedback (we would love it) after choosing an option 👇 |
Enjoy this newsletter? Forward to a friend and have them signup here.